Sector News

AstraZeneca’s MedImmune To Acquire Definiens

November 4, 2014
Life sciences
(RTTNews.com) – Astrazeneca plc Tuesday said its global biologics research and development arm, MedImmune, has agreed to buy privately-held Definiens, which would strengthen MedImmune’s focus on the discovery of novel predictive biomarkers in immuno-oncology.
 
Definiens is into imaging and data analysis technology, known as Tissue Phenomics, which dramatically improves the identification of biomarkers in tumour tissue.
 
Under the agreement, MedImmune will acquire Definiens’ shares for an initial payment of $150 million and make additional predetermined milestone payments.
 
Bahija Jallal, Executive Vice President of MedImmune commented: “Definiens’ technology will complement our immuno-oncology approach and allow us to accelerate further our clinical programmes through its highly precise predictive and prognostic biomarker testing.”
 
The transaction is expected to close in the fourth quarter of 2014.
 

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).